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The antibacterial activities of a series of triazolyl oxazolidinones against Mycobacterium tuberculosis strain in vitro and in vivo in
a mice model are presented. Most active compounds were noncytotoxic against VERO cells with acceptable selectivity indexes
(SI) as measures of compound tolerability. Structure activity relationships (SARs) revealed that analogs with alkylcarbonyl (IC90:
< 0.2 to 0.422μg/mL) and arylcarbonyl (IC90: < 0.2 to 2.103μg/mL) groups at the piperazine 4N-position-displayed potent
antimycobacterium activities, comparable to the methanesulfonyl (IC90: < 0.2μg/mL) analog, linezolid (IC90: < 0.2μg/mL), and
isoniazid (IC90: < 0.034μg/mL). The furanylcarbonyl derivative also displayed potent activity, while the arylsulfonyl analogs were
inactive. Of the triazolyl oxazolidinones, the morpholino (PH-27) derivative with medium bioavailability in plasma was most
active in vivo, but relatively less eﬃcacious than isoniazid.
1.Introduction
Tuberculosis (TB) caused by Mycobacterium tuberculosis,
a contagious and fatal disease, is considered a global
epidemicandamajorthreattopublichealth.TBisbecoming
more prevalent in the world today than any other time in
human history. It has been estimated that over a third of the
world’s population is infected with the TB bacilli, with 9.4
millionnewcasesandnearly1.7milliondeathsin2009[1,2].
Most infected people harbor latent TB infection (LTBI), and
people with HIV/AIDS and compromised immune system
are more likely to develop the disease. TB continues to be a
leadingcauseofdeathinHIV/AIDSpatients,formingalethal
combination.
A number of drugs, namely, isoniazid, rifampicin,
ethambutol, and pyrazinamide are often administered over
a prolonged period of time and may lead to the development
of resistant strains due to patient-poor compliance among
other factors. The development and spread of resistant M.
tuberculosis,poseavitalchallengetothecontrolofTBworld-
wide. In recent years, the emergence and spread of resistant
M.tuberculosisstrainshasfuelledtheTBepidemicbymaking
it more diﬃcult to treat. Multidrug-resistant (MDR) TB,
which is resistant to the ﬁrst line anti-TB agents, namely,
isoniazid and rifampicin are increasing with >500,000/yr
new cases of MDR-TB worldwide [3, 4]. Extensively drug-
resistant (XDR) TB, resistant to ﬁrst line anti-TB agents,
namely, isoniazid, rifampicin, ﬂuoroquinolones, and one
of three injectable drugs, such as capreomycin, kanamycin,
or amikacin is awfully diﬃcult to treat and is considered
a worldwide threat to TB control [3, 4]. These statistics
serve as impetus for development of more eﬀective and safer
anti-TB drugs [5]. For more than 40 years, there has been
a drought of new anti-TB drugs. However, more recently,
there are increasing reports of newer agents demonstrating
activity against drug-resistant M. tuberculosis strains [5–8].
Among these new agents are the oxazolidinones (linezolid—
LZD;a n dPNU-100480; Figure 1), diarylquinoline (TMC-
207; Figure 1), the nitroimidazole-oxazole (OPC-67683;
Figure 1), the nitroimidazo-oxazine (PA-824, Figure 1), and
some quinolone class of compounds. Linezolid (LZD;
Figure 1), a prototypical oxazolidinone used in the clinic to
treat gram-positive bacterial infections, the thiomorpholino
derivative of LZD (PNU-100480; Figure 1), and others in2 Tuberculosis Research and Treatment
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PH-27: X = O
1a-p: X = N-COR (R = H, alkyl, cycloalkyl)
2a-m: X = N-COR (R = aryl, heteroaryl)
3a-e: X = N-S(O)2R (R = alkyl, aryl)
Figure 1: Chemical structure of oxazolidinone antibacterial agents and novel antimycobacterial agents.
this class, have demonstrated activity against susceptible and
drug-resistant M. tuberculosis. Our laboratories have been
interested in the synthesis of triazolylmethyl oxazolidinones
of general structures PH-27, 1, 2,a n d3 (Figure 1)w i t h
antibacterial activity [9–12]. Studies from other laboratories
and ours have shown that the triazolyl oxazolidinones have
potentactivityagainstgram-positivebacterialspecies[9–14],
comparable or superior to linezolid in vitro,t h u sa ﬃrming
the bioisosteric replacement of the C5 acetamido functional
group by the triazolyl moiety. On the basis of the potent
antibacterial activities of the triazolyl oxazolidinones and
the demonstrated antimycobacterium activities of repre-
sentative oxazolidinones, namely, LZD and PNU-100480,
we evaluated the antiMycobacterium tuberculosis activity of
selected novel triazolylmethyl oxazolidinones synthesized
from our laboratories. Therefore, this study outlines the
in vitro and in vivo antimycobacterial activity of selected
triazolylmethyl oxazolidinones and to establish observable
qualitative structure-activity relationships.
2.MaterialsandMethods
2.1. Synthesis of Compounds. The preparation of the com-
pounds 1a-p, 2a-m,a n d3a-e has been described previ-
ously [9–12]. The reference antituberculosis agents isoniazid
(INH) and linezolid (LZD) were provided by the Tuber-
culosis Antimicrobial Acquisition and Coordinating Facility
(TAACF), Southern Research Institute, Birmingham, AL.,
USA.
2.2. Antituberculosis Susceptibility Testing. The in vitro anti-
tubercular testing was determined according to the protocols
of the Tuberculosis Antimicrobial Acquisition and Coor-
dinating Facility (TAACF), USA [15, 16]. The activity of
all compounds against replicating M. tuberculosis H37Rv
(ATCC 27294, American Type Culture Collection, Rockville,
MD, USA) was performed in BACTEC 12B medium using
a ﬂuorescence readout in the Microplate Alamar Blue Assay
(MABA) according to the TAACF initial primary screen
assays. Compounds were dissolved in 80% DMSO or 60%
EtOH in water or H2O and tested in ten 2-fold dilutions,
ranging from 0.19 to 100μg/mL; the IC90 (μg/mL) values
deﬁnedas“inhibitoryconcentration”eﬀectingareductionin
ﬂuorescence of 90% relative to the controls. The values were
determined from dose-response curves, and compounds
with IC90 ≤ 10μg/mL were considered active for anti-
tubercular activity.
2.3. Mammalian VERO Cell Cytotoxicity (CC50) Assay. The
compounds were screened to assess toxicity to African green
monkey kidney (VERO) cells using the Promage’s Cell Titer
Glo Luminescent Cell Viability assay by TAACF. The assay
returns a CC50 value, which allows a selectivity index (SI:
ratio of CC50/IC90) to be calculated. Compounds with SI
value ≥ 10 are considered safe for further screening.
2.4. Preliminary In Vivo Bioavailability Testing (BioAssay).
All in vivo assays/evaluations were determined according toTuberculosis Research and Treatment 3
Table 1: In vitro antimycobacterium activity of 4N-acylpiperazinyl oxazolidinones against M. tuberculosis H37Rv.
O
N
O
N N
F
N N N R
Compd. –R Clog P
values
IC90 (μg/mL) CC50 (μg/mL) VERO SI
1a HCO −1.1502 <0.20 >37.43 >187.1
b CH3CO −1.2042 <0.20 >41.64 >208.2
c CF3CO −0.0952 0.281 >44.23 >156.8
d CHCl2CO 0.1218 <0.20 >45.72 >228.6
e CH3CH2CO −0.6752 0.334 >40.24 >120.4
f CH3CH2OCO 0.9748 0.422 >41.84 >98.91
g (CH3)2CHCO −0.3662 0.283 >41.64 >146.6
h (CH3)3COCO 1.6828 <0.20 >44.64 >223.2
i CH3(CH2)4CO 0.9118 <0.20 >44.45 >222.2
j cyclohexanoyl 0.8268 2.095 >45.65 >21.79
k CH3(CH2)5CO 1.4408 <0.20 >45.85 >229.2
l CH3(CH2)6CO 1.9698 <0.20 >47.25 >236.2
m CH3(CH2)7CO 2.4988 <0.20 >48.65 >243.2
n CH3(CH2)8CO 3.0278 <0.20 >50.06 >250.3
o CH3(CH2)9CO 3.5568 <0.20 >51.46 >257.3
p
O
1.7208 <0.20 >48.25 >241.2
PH-27 O N
F
N
O
O
N
N
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0.6308 0.466 >34.73 >74.53
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H
N
O
O
O
N
F
N O
CH3 0.5321 <0.20 >33.73 >168.6
INH
O
N
HN NH2
−0.668 0.034 >100 >2941
the TAACF protocols [15]. This assay was used to estimate
drug levels in mice at speciﬁc time points after oral dosing,
using the inhibition of growth of M. tuberculosis H37Rv
as an indicator for drug activity. Selected compounds were
orally dosed (300mg/kg in 0.5% methyl cellulose) in three
C57BL/6 mice and the animals were bled by nicking the
lateral vein at 30mins and 2.5hrs, respectively, to collect
blood samples. The blood samples were allowed to clot and
centrifuged to collect serum, which were serially diluted
and added to 96-well assay plates containing M. tuberculosis
H37Rv (104 bacterial) on 100μL 7H9 broth with 10%
serum. Each assay also contains lanes of wells with drugs of
known concentrations, with or without 10% mouse serum.
Inhibition of bacterial growth was determined by optical
density (λ = 600nm) measurements every 3-4 days up
to 14 days. The results were further conﬁrmed by visual
inspection at 10 days. Inhibition of bacterial growth in the
assay (<50% of control without drugs) indicates suﬃciently
high concentration of compound in blood and hence an
acceptable bioavailability.
2.5. In Vivo Eﬃcacy Gamma Knock-Out (GKO) Mouse Model.
Interferon gamma knockout female mice C57BL/6 IFN-KO
(n = 5) unable to control an infection of M. tuberculosis were4 Tuberculosis Research and Treatment
Table 2: In vitro antimycobacterium activity of 4N-arylcarbonyl- and 4N-arylsulfonyl-piperazinyl oxazolidinones against M. tuberculosis
H37Rv.
O
NN N R
O
N
N
N
F
Compd. –R Clog P
values
IC90 (μg/mL) CC50 (μg/mL) VERO SI
2a PhCO 0.6148 0.722 >45.04 >62.3
b 4-ClPhCO 1.4304 <0.20 >48.49 >242.4
c 3-NO2PhCO 0.5198 0.759 >49.54 >65.27
d 2-CH3PhCO 1.1138 3.375 >46.45 >13.76
e 3-CH3PhCO 1.1138 0.422 >46.45 >110
f 4-CH3PhCO 1.1138 2.103 >46.45 >22.08
g 2-CH3OPhCO 0.8347 1.04 >48.05 >46.15
h 3-CH3OPhCO 0.8347 0.829 >48.05 >57.89
i 4-CH3OPhCO 0.8347 0.843 >48.05 >56.93
j 2-furylCO −0.2092 <0.20 >44.04 >220.2
k 2-thienylCO 0.3913 0.209 >45.65 >217.3
l 3-pyridylCO −0.4862 0.236 >45.14 >190.4
m 2-Cl 3-pyridylCO 0.2641 1.389 >48.59 >34.98
3a CH3SO2 −0.6042 <0.20 >42.44 >212.2
b 2-furylSO2 1.0658 >100 (0.419)a n/d n/d
c PhSO2 1.3448 5.469 >48.65 >8.896
d 3-CH3PhSO2 1.8438 >100 (1.024)a n/d n/d
e 4-CH3PhSO2 1.8438 >100a n/d n/d
PH-27 O N N
F
O
O
N
N
N
0.6308 0.466 >34.73 >74.53
LZD
O N
F
N
O
O H
N
O
CH3 0.5321 <0.20 >33.73 >168.6
INH N
O
HN NH2
−0.668 0.034 >100 >2941
aConcentration that inhibited 50% growth of M. tb.( I C 50).
infected with M. tuberculosis ATCC 35801 (Erdman strain)
by aerosol infection utilizing the Glass-Col Inhalation Expo-
sure System. Treatment was started on day 13 after infection
for 9 consecutive daily treatments until day 21. Test com-
pounds were dissolved in 0.5% methyl cellulose and admin-
istered via oral gavage. An isoniazid (INH) control group,
administered via oral gavage at 25mg/Kg/day (H2O), was
includedineachstudy.Miceweresacriﬁcedonday22postin-
fection, and bacterial loads in the lungs and spleen were
determined [15]. The Log10CFU reduction values > 0.30
generally indicate activity.
3. Results and Discussion
The main goals of this study included evaluating the antimy-
cobacterial activities of a series of triazolyl oxazolidinone
derivatives 1a-p and 2a-m and 3a-e, in vitro and in vivo, and
explore recognizable structure-activity relationships (SARs)
around the phenyloxazolidinone moiety. The synthesis of
the compounds was described previously [9–12]. The results
from the in vitro and in vivo (mice model) studies, presented
in the Tables 1–5, were determined according to TAACF
protocols [15, 16]. Data from in vitro antimycobacteriumTuberculosis Research and Treatment 5
Table 3: In vivo bioavailability of selected oxazolidinones.
Compd. ∼ MIC (μg/mL)
− serum
∼ MIC (μg/mL)
+s e r u m
Dilution factora ∼ Compd in serum (μg/mL) Bioavailabilityb
1g 1.1 3.3 1:20 22 low
1i 3.3 3.3 0 0 none
1o 0.37 3.3 0 0 none
2b 3.3 3.3 0 0 none
2j 1.1 1.1 0 0 none
2k 1.1 1.1 0 0 none
2l 1.1 0.37 1:10 11 low
3a 0.37 1.1 0 0 none
PH-27 1.1 0.37 1:80 88 medium
LZD 0.37 0.37 1:320 118.4 high
INH 0.014 0.041 1:320 4.48 high
aDilution factor represents the last dilution step of the serum samples in which drug activity was still observed in the bioassay. (Drug levels in mouse serum
are estimated by multiplying the dilution factor by the MIC value of the drug in absence of serum).
bRating of bioavailability: low: activity of drug can be seen in 1 or 2 wells of the bioassay; medium: activity of drug can be seen in 3 or 4 wells of the bioassay;
high: activity of drug can be seen in 5 or 6 wells.
Table 4: In vivo eﬃcacy and observation at time of sacriﬁce.
Compd. Lungs Spleen Other remarks
Control +++ 6 enlarged; 1 very large 2 with enlarged lymph nodes
INH + 1 slightly enlarged; 4 normal n/a
2l (306019) ++ 1 enlarged; 4 slightly enlarged Large intestine distended full of feces and air
1g (306027) + 1 slightly enlarged; 4 normal Large intestine distended full of feces and air
PH-27 (306006) + normal Large intestine distended full of feces and air
+++; highly infected. ++/+; hardly any infected. n/a; not applicable.
and VERO cytoctoxicity assays are presented in Tables 1
and 2. From these data most of the compounds displayed
potent to lack of activity against M. tuberculosis H37Rv
strain with IC90 values in the range of <0.2 to >100μg/mL,
while the reference compounds linezolid (LZD) and isoni-
azid (INH) showed IC90 values of <0.2 and 0.034μg/mL,
respectively. The 4N-acylpiperazinyl derivatives displayed
potent activity (IC90 range of >0.2–0.422μg/mL, Table 1),
in comparison to the 4N-aryl-carbonylpiperazinyl deriva-
tives, which were relatively less active with IC90 in the
range of <0.2–2.103μg/mL. On the other hand, the 4N-
arylsulfonyl derivatives were devoid of antimycobacterium
activity(IC90 rangeof5.469–100μg/mL),whilethemethane-
sulfonylpiperazinyl derivative 3a showed potent activity with
IC90 value of <0.2μg/mL. Although positive correlations
between log P values and antimycobacterium activity have
been demonstrated by previous other studies [17], however,
such correlations could not be drawn in the present study
since the MIC end-points were not determined. The ClogP
values of the compounds were estimated using ChemDraw
Ultra 8.0.
In this study, interpretation of the in vitro assays (IC90
and VERO cell cytotoxicity: CC50) data assisted in selection
of compounds for further testing in vivo.H e n c e ,d a t af r o m
the selectivity index (SI ratio = CC50/IC90, Tables 1 and 2)
further indicated that most of the active compounds also
displayed acceptable safety and therapeutic index proﬁles,
represented by their SI ranges of >21 to >250. According
to the TAACF criteria, compounds with SI value ≥ 10 are
considered safe for further screening. In this regard, nine
triazolyl oxazolidinones (1g,1i,1o,2b,2j,2k,2l,3a,a n dPH-
27) along with LZD and INH as reference compounds were
selected for preliminary bioavailability study. This bioassay
was used to estimate the levels of the drug in mice at
speciﬁc times after oral dosing. From the results presented in
Table 3, the reference compounds LZD and INH displayed
high concentrations (118.4 and 4.48μg/mL) of the drugs in
mice serum, suggesting high bioavailability of the drugs as
demonstrated by the activity against M. tuberculosis H37Rv
in 5 or 6 wells. While three of the triazolyl oxazolidinones,
namely, 1g (4N-isobutyryl), 2l (4N-nicotinoyl), and PH-27
(morpholino) displayed low to medium concentrations in
mice, indicating low-to-medium bioavailability of drugs as
demonstrated by activity in only 1 or 2 and 3 or 4 wells of
the bioassay, respectively. In addition, the most lipophilic
compound, the 4N-undecanoyl derivative 1o (ClogP =
3.5568) demonstrated 10 times higher MIC in the presence
of serum suggesting that this compound probably has higher
protein binding. Although all the other 5 compounds tested
alsoshowedrelativelyinsigniﬁcantproteinbinding(Table 3),
they also demonstrated no bioavailability similar to that of
4N-undecanoylderivative1o.Theprobablereason(s)forthis6 Tuberculosis Research and Treatment
Table 5: In vivo eﬃcacy log10CFU reduction in bacterial load in lungs and spleen.
Test group Organ Dose
mg/Kg/dy
Mean ± SEMCFU Log10CFU reduction Activity
Untreated d13 Lung
n/a
6.90 ± 0.11 n/a n/a
Spleen 4.75 ± 0.21
Untreated d22 Lung
n/a
8.06 ± 0.11 n/a n/a
Spleen 6.38 ± 0.07
INH Lung
25
4.77 ± 0.12 3.29 Active
Spleen 2.04 ± 0.38 4.34 Active
2l (306019) Lung
150
7.67 ± 0.22 0.39 Inactivea
Spleen 6.24 ± 0.06 0.14 Inactivea
1g (306027) Lung
300
7.28 ± 0.14 0.78 Slightly active
Spleen 5.95 ± 0.09 0.43 Inactivea
PH-27 (306006) Lung
150
6.62 ± 0.08 1.44 Active
Spleen 4.64 ± 0.21 1.74 Active
a306027: slightly active in lung, but activity in spleen was not statistically signiﬁcant.
lack of bioavailability of these other 5 compounds could be
due to rapid metabolism and/or poor permeability of the
compounds.
Finally, the in vivo antimycobacterial activities of the
compounds that displayed bioavailability of low to high
concentrations were evaluated against gamma knock-out
(GKO) C57BL/6 female mice model, which are unable to
control aerosol infection with the Erdman strains ATCC
35801. Treatment was initiated 13 days after infection by
orally administering the drugs and treatment continued for
9 consecutive days until 21 days. The results of this in vivo
study are presented in Tables 4 and 5 following sacriﬁce of
the animals. As can be seen in Table 4, the triazolyl oxazo-
lidinones 1g (306027) and PH-27 (306006) demonstrated
eﬃcacy comparable to INH in mice lungs and spleen, while
2l (306019) were less eﬃcacious. Generally, the triazolyl
compounds were more eﬀective in lungs. Furthermore, mice
treated with the triazolyl oxazolidinones presented with
distended large intestine. The morpholino derivative PH-27
was the most active of the triazolyl oxazolidinones tested
providing 1.44logCFU reduction in the lung and 1.74log
reduction in the spleen. While the 4N-isobutyryl derivative
1g showed 0.78logCFU reduction in the lungs, which was
statistically signiﬁcant, but no statistically signiﬁcant activity
was noted in the spleen. On the contrary, the 4N-nicotinoyl
derivative 2l did not show statistically signiﬁcant logCFU
reductionineitherlungorspleenwith0.39and0.14logCFU
(Table 5), respectively. However, the reference compound
INH provided 3.29log and 4.3 4l o gC F Ur e d u c t i o ni nl u n g s
and spleen, respectively.
The main reason for the signiﬁcant diﬀerences in the
in vivo eﬃcacy of these three derivatives 4N-isobutyryl 1g,
4N-nicotinoyl 2l, and morpholino PH-27 is not clear, apart
from the obvious diﬀerences in the preliminary bioavail-
ability results. Although the bioavailability studies of the
eﬃcacious compounds are very preliminary in nature, the
eﬃcacy results seem to go well in hand with the reported
oral exposure of the compounds. Previous studies from
our laboratory have shown that these class of compounds
are relatively stable in plasma at physiologic conditions
and may bind to plasma protein [18]. In particular, the
most probable reasons for lack of bioavailability of the six
triazolyl oxazolidinones 1i, 1o, 2b, 2j, 2k,a n d3a may be
due to rapid in vivo metabolism and/or poor permeability
upon oral administration. Further investigations on these
class of compounds and other derivatives including their
monoamine oxidase inhibitory activities are ongoing in our
laboratories.
4. Conclusion
This study discloses the in vitro and in vivo antimycobac-
terium activity of a series of triazolyl oxazolidinones. Most of
the compounds displayed potent in vitro activity against M.
tuberculosis H37Rv, but this in vitro potency was not strongly
reﬂectedatthesamelevelinvivo.Thiscouldbeduetothelow
bioavailabilityofthecompoundsinvivo,however,theprecise
reason for this is unresolved. In conclusion, these derivatives
may serve as templates for further modiﬁcations to attain
more eﬀective antimycobacterial compounds.
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